Loyal Valley Capital led a $186m Series C round for CARsgen Therapeutics.

Loyal Valley Capital, a thematic, research-driven private equity firm, led a $186m Series C round for CARsgen Therapeutics, a biotechnology company focused on innovation and development of chimeric antigen receptor T-cell therapeutics. LVC was joined by investors Lilly Asia Ventures, Shiyu Capital, and Summer Capital and South China Venture Capital. "I am pleased that CARsgen has repeatedly received recognition and support from leading financial institutes and professional investors. This Series C funding will accelerate CARsgen's ongoing clinical trials in China, the United States, and Europe, and will support expanding our commercial manufacturing facilities. It advances the company's global development activities as we work to launch CARsgen's leading products for the benefit of cancer patients worldwide," Dr. Zonghai Li, CARsgen Founder, President, CEO, and CSO.